Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease

Abstract

AimsInsulin resistance (IR) plays a pivotal role in the pathogenesis of Metabolic dysfunction‐Associated Fatty Liver Disease (MAFLD), which can progress to liver fibrosis. We examined the relationship of different IR scores with markers of MAFLD severity in obese individuals.Materials and MethodsIn this retrospective observational study, 346 non‐diabetic, overweight/obese individuals with newly diagnosed MAFLD (age 50.2 ± 13.3 years, 34% females, BMI 30.8 ± 4.4 kg/m2) underwent liver stiffness (LS) and controlled attenuation parameter (CAP) measurements by Fibroscan® to assess liver fibrosis and steatosis. Biochemical data were collected to calculate surrogate markers of IR (Homoeostasis model assessment ‐ insulin resistance index [HOMA‐IR], triglyceride‐glucose index, triglyceride by HDL ratio), liver fibrosis (Nonalcoholic Fatty Liver Diseases fibrosis score, fibrosis‐4 score, Aspartate aminotransferase to platelet ratio index) and steatosis (fatty liver index, hepatic steatosis index).ResultsAll three IR scores were associated with CAP, while only HOMA‐IR positively correlated with LS (r = 0.275, p < 0.0001), independent of age and sex, BMI, transaminases, and fibrosis markers. Insulin‐resistant individuals (HOMA‐IR >2.5, n = 165) had higher liver enzymes, CAP and LS, with a 4‐fold increased risk of severe liver disease (LS >9.7 kPa, OR 4.42[1.95–10.01], p = 0.0002). Among HOMA‐IR components, fasting plasma insulin (FPI) was independently associated with LS (r = 0.270, p < 0.0001). ROC AUC for HOMA‐IR and FPI to predict severe liver disease were virtually identical (0.748 and 0.758, respectively).ConclusionsHOMA‐IR is independently associated with non‐invasive markers of MAFLD severity in overweight/obese individuals. This relationship is largely mediated by hyperinsulinemia, regardless of BMI. Measuring insulin levels in MAFLD individuals might be useful to identify those at risk of liver fibrosis.

The determination of the comparative effect of Ertugliflozin, Pioglitazone, and Metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus.

“…Furthermore, thiazolidinediones that lower adipose tissue dysfunction, insulin resistance, and in ammation are proven to be advantageous in these patients (Musso et al, 2017). The studies utilizing pioglitazone have shown amelioration in insulin resistance as well as in histology and laboratory ratio of liver function in patients with fatty liver (Lingvay et al, 2021;Petralli et al, 2023; M. J. . This study aimed to determine the effect and safety of pioglitazone, metformin, and ertugli ozin in NAFLD with type 2 diabetes mellitus (T2DM).…”